PSMA PET/CT for prostate cancer diagnosis: current applications and future directions

PSMA PET/CT for prostate cancer diagnosis: current applications and future directions

Abstract Prostate cancer (PCa) requires improved diagnostic strategies beyond conventional imaging. This review aimed to evaluate the role of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in diagnosing advanced PCa. The review analyzed the diagnost...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhengang Shen, Zeng Li, Yunlong Li, Xiaodi Tang, Jiayi Lu, Li Chen, Zhu Zhong Cheng, Hong Liao, Shukui Zhou
Format:	Article
Language:	English
Published:	Springer 2025-05-01
Series:	Journal of Cancer Research and Clinical Oncology
Subjects:	Prostate cancer (PCa) PSMA PET/CT (Prostate-specific membrane antigen positron emission tomography/Computed tomography) Locoregional staging Pelvic lymph node metastasis Metastatic prostate cancer Biochemical recurrence
Online Access:	https://doi.org/10.1007/s00432-025-06184-z
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
by: Cato C. Loeff, et al.
Published: (2024-11-01)

Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer
by: Laura Bauersachs, et al.
Published: (2025-07-01)

Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review
by: Soroush Rais-Bahrami, et al.
Published: (2025-05-01)

Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study
by: Le Ma, et al.
Published: (2025-01-01)

PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy
by: Ruohua Chen, et al.
Published: (2025-07-01)

Cinematic rendering of 18F‐DCFPyL PET/CT fusion data in a patient with metastatic clear cell renal cell carcinoma
by: Steven P. Rowe, et al.
Published: (2024-06-01)

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
by: Atefeh Zamanian, et al.
Published: (2025-07-01)

Indications and Results for Ga-68 PSMA PET/CT in Patients with Biochemical Relapse of Prostate Cancer
by: Ivan Rogić, et al.
Published: (2024-01-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer
by: Anna-Lena Zang, et al.
Published: (2025-09-01)

PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
by: Nicole Handa, et al.
Published: (2025-05-01)

PSMA PET/CT scan reveals incidental meningioma in a prostate cancer patient
by: Venetia A. Florou, et al.
Published: (2025-05-01)

The value of habitat analysis based on 18F-PSMA-1007 PET/CT images for prostate cancer risk grading
by: Yang Wang, et al.
Published: (2025-07-01)

A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer
by: Matthew J. Roberts, et al.
Published: (2025-07-01)

The impact of patient hydration and forced diuresis on [18F]PSMA-1007 urinary bladder uptake in PET/CT imaging
by: Aleksandr Igorevich Khalimon, et al.
Published: (2025-06-01)

Testing the diagnostic accuracy of a 68Ga-PSMA PET Scan in Early Biochemical Recurrence of Prostate Cancer
by: Vigna-Taglianti Riccardo, et al.
Published: (2024-10-01)

The impact of preliminary patient hydration on physiological [18F]PSMA-1007 uptake in the urinary bladder on PET/CT
by: T. L. Antonevskaya, et al.
Published: (2024-06-01)

Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era
by: Juan Gómez Rivas, et al.
Published: (2025-05-01)

68Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy
by: Yuigi Yuminaga, et al.
Published: (2021-04-01)

Comparison of 18F-FDG and 68-PSMA-11 in PET for prostate cancer diagnosis
by: Natalia Fulle, et al.
Published: (2022-12-01)

Unexpected discovery of hepatic cancer via 68Ga-PSMA PET/CT in the staging of prostate cancer
by: Radu Alexa, et al.
Published: (2025-06-01)

Preliminary clinical study of p-iodo benzoyl moiety-modified PSMA inhibitors and prospective comparison with 68Ga-PSMA-11
by: Jianpeng Cao, et al.
Published: (2025-06-01)

A fully automated AI-based method for tumour detection and quantification on [18F]PSMA-1007 PET–CT images in prostate cancer
by: Elin Trägårdh, et al.
Published: (2025-08-01)

The Performance and Role of PSMA PET Scans in Localised Prostate Cancer
by: Jianliang Liu, et al.
Published: (2025-02-01)

A pilot study of PSMA-targeted F-18-DCFPyL PET imaging of patients with adenoid cystic carcinoma
by: Andrew F. Voter, et al.
Published: (2025-05-01)

MODERN OPPORTUNITIES OF PET/CT IN THE DIAGNOSIS OF PROSTATE CANCER
by: V. V. Vyazmin, et al.
Published: (2021-10-01)

A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: An initial experience
by: Manoj Gupta, et al.
Published: (2017-07-01)

Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
by: Marcus Edward Asokendaran, et al.
Published: (2019-07-01)

THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER
by: Duygu Has Şimşek, et al.
Published: (2021-01-01)

Preclinical and clinical evaluation of [64Cu]Cu-PSMA-Q PET/CT for prostate cancer detection and its comparison with [18F]FDG imaging
by: Fei Chen, et al.
Published: (2025-04-01)

Diagnostic value of [18F]PSMA-1007 PET/CT based on PRIMARY score combined with mpMRI in clinically significant prostate cancer
by: Zhilong Ma, et al.
Published: (2025-06-01)

Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients
by: Aravintho Natarajan, et al.
Published: (2019-07-01)

A population‐based analyses of the evolving management of cN1M0 prostate cancer in the PSMA‐PET era
by: Jennifer Ward, et al.
Published: (2025-07-01)

Updates on controversies surrounding the staging and management of newly diagnosed localized prostate cancer using prostate-specific membrane antigen (PSMA) positron emission tomography
by: Patricia Tai, et al.
Published: (2025-07-01)

Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer
by: Negar Abdi, et al.
Published: (2025-03-01)

High Detection Rates for Prostate-specific Membrane Antigen–avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography
by: Sarah Thomas, et al.
Published: (2025-01-01)

Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?
by: Kambiz Rahbar, et al.
Published: (2020-07-01)

Case report: Malignant priapism: penile metastasis from prostate cancer with low serum PSA level
by: Zhiqiang Zhang, et al.
Published: (2025-01-01)

How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View
by: Daniela E. Oprea-Lager, et al.
Published: (2025-05-01)

Preoperative detection of extraprostatic tumor extension in patients with primary prostate cancer utilizing [68Ga]Ga-PSMA-11 PET/MRI
by: Clemens P. Spielvogel, et al.
Published: (2024-12-01)